In summary, in this study, we observed that tumour PD-L1, stromal infiltration of CD3+ immune cells, combined tumour and stromal infiltration of CD8+ immune cells, combined stromal infiltration of PD-1+ and CD8+ immune cells and combined stromal infiltration of PD-L1+ and CD8+ immune cells are associated with DCB on nivolumab treatment. Here, CD8A is linked to neoplasm.